Epoch Investment Partners, Inc. Vanda Pharmaceuticals Inc. Transaction History

Epoch Investment Partners, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$6.18 - $7.99 $4.27 Million - $5.52 Million	-690,707 Reduced 49.43%	706,570 $4.8 Million
Q4 2022 Feb 13, 2023	SELL	$6.87 - $10.96 $9.12 Million - $14.5 Million	-1,326,875 Reduced 48.71%	1,397,277 $10.3 Million
Q3 2022 Nov 14, 2022	SELL	$9.44 - $11.76 $316,183 - $393,889	-33,494 Reduced 1.21%	2,724,152 $26.9 Million
Q2 2022 Aug 15, 2022	BUY	$9.31 - $11.84 $1.66 Million - $2.11 Million	178,434 Added 6.92%	2,757,646 $30.1 Million
Q1 2022 May 13, 2022	BUY	$10.84 - $16.55 $6.7 Million - $10.2 Million	617,829 Added 31.5%	2,579,212 $29.2 Million
Q4 2021 Feb 11, 2022	SELL	$15.69 - $21.14 $306,174 - $412,525	-19,514 Reduced 0.99%	1,961,383 $30.8 Million
Q3 2021 Nov 12, 2021	BUY	$15.35 - $21.27 $2.09 Million - $2.9 Million	136,207 Added 7.38%	1,980,897 $34 Million
Q2 2021 Aug 13, 2021	BUY	$15.71 - $21.51 $10.8 Million - $14.7 Million	685,481 Added 59.13%	1,844,690 $39.7 Million
Q1 2021 May 17, 2021	BUY	$13.42 - $20.28 $15.6 Million - $23.5 Million	1,159,209 New	1,159,209 $17.4 Million

161

45.2M

165K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $264M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Epoch Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Epoch Investment Partners, Inc. with notifications on news.